KR100819575B1 - 플라본, 잔톤 및 쿠마린의 신규 유도체 - Google Patents

플라본, 잔톤 및 쿠마린의 신규 유도체 Download PDF

Info

Publication number
KR100819575B1
KR100819575B1 KR1020027002800A KR20027002800A KR100819575B1 KR 100819575 B1 KR100819575 B1 KR 100819575B1 KR 1020027002800 A KR1020027002800 A KR 1020027002800A KR 20027002800 A KR20027002800 A KR 20027002800A KR 100819575 B1 KR100819575 B1 KR 100819575B1
Authority
KR
South Korea
Prior art keywords
compound
yne
group
formula
morpholinobut
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027002800A
Other languages
English (en)
Korean (ko)
Other versions
KR20020030801A (ko
Inventor
봄바르델리에지오
발렌티피에로
Original Assignee
인데나 에스피아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인데나 에스피아 filed Critical 인데나 에스피아
Publication of KR20020030801A publication Critical patent/KR20020030801A/ko
Application granted granted Critical
Publication of KR100819575B1 publication Critical patent/KR100819575B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86—Oxygen atoms, e.g. xanthones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
KR1020027002800A 1999-09-03 2000-08-28 플라본, 잔톤 및 쿠마린의 신규 유도체 Expired - Fee Related KR100819575B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9920912.4 1999-09-03
GBGB9920912.4A GB9920912D0 (en) 1999-09-03 1999-09-03 Novel derivatives of flavones,xanthones and coumarins

Publications (2)

Publication Number Publication Date
KR20020030801A KR20020030801A (ko) 2002-04-25
KR100819575B1 true KR100819575B1 (ko) 2008-04-04

Family

ID=10860348

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027002800A Expired - Fee Related KR100819575B1 (ko) 1999-09-03 2000-08-28 플라본, 잔톤 및 쿠마린의 신규 유도체

Country Status (20)

Country Link
US (1) US6608089B2 (https=)
EP (1) EP1212312B1 (https=)
JP (1) JP4782337B2 (https=)
KR (1) KR100819575B1 (https=)
CN (1) CN1229370C (https=)
AT (1) ATE236147T1 (https=)
AU (1) AU775790B2 (https=)
CA (1) CA2382129C (https=)
CZ (1) CZ300939B6 (https=)
DE (1) DE60001974T2 (https=)
DK (1) DK1212312T3 (https=)
ES (1) ES2195933T3 (https=)
GB (1) GB9920912D0 (https=)
HU (1) HUP0202578A3 (https=)
NO (1) NO327911B1 (https=)
PL (1) PL211887B1 (https=)
PT (1) PT1212312E (https=)
RU (1) RU2252221C2 (https=)
SK (1) SK286402B6 (https=)
WO (1) WO2001017985A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200001861A (ko) 2018-06-28 2020-01-07 영남대학교 산학협력단 잔톤 유도체의 신규한 제조방법, 이로 제조된 신규한 잔톤 유도체 및 이들을 포함하는 조성물

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
PL205635B1 (pl) * 2001-04-09 2010-05-31 Inst Farmaceutyczny Nowe pochodne genisteiny i zawierające je środki farmaceutyczne
AU2003234733B2 (en) 2002-04-17 2009-01-29 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005533119A (ja) 2002-07-17 2005-11-04 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
DE60333112D1 (de) * 2002-08-02 2010-08-05 Univ Ohio State Res Found 2-heterosubstituierte 3-aryl-4-h-1-benzopyran-4-one als neue therapeutika bei brustkrebs
EP1554265A4 (en) * 2002-09-13 2008-05-07 Cytokinetics Inc COMPOSITIONS, COMPOSITIONS AND M THODES
US20060135445A1 (en) * 2003-02-04 2006-06-22 Kabushiki Kaisha Yakult Honsha Breast cancer-resistant protein inhibitor
CA2523178C (en) * 2003-03-24 2012-10-23 Luitpold Pharmaceuticals, Inc. Materials and methods to potentiate cancer treatment
JP2007507539A (ja) * 2003-10-06 2007-03-29 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
GB0412768D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
FR2929276B1 (fr) * 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN101497593B (zh) * 2009-03-18 2011-09-21 华南理工大学 5-羟基香豆素和吡喃型香豆素类化合物及合成方法与应用
EP2560652A4 (en) * 2010-04-23 2013-08-14 Kineta Inc ANTIVIRAL CONNECTIONS
CN101985449B (zh) * 2010-09-28 2012-08-22 中山大学 一种香豆素衍生物及其制备方法和作为抗癌药物的用途
CN103113340B (zh) * 2013-01-21 2015-08-19 四川大学 一类金雀异黄酮烷基胺类化合物、其制备方法和用途
CN103232462B (zh) * 2013-05-13 2016-03-02 湖北科技学院 香豆素-吡咯类化合物的合成方法
CN103408554B (zh) * 2013-07-31 2015-07-08 西安交通大学 一种具有降高血压活性的吡咯香豆素类化合物及制备方法
CN104274455B (zh) * 2014-09-24 2018-04-27 山东理工大学 含苄基哌嗪槲皮素衍生物制法及其对胃黏膜保护作用
CN107641109B (zh) * 2017-10-16 2019-05-24 厦门大学 一种类黄酮化合物及其制备方法和应用
CN107602520B (zh) * 2017-10-16 2019-06-14 厦门大学 一种含哌嗪环的类异黄酮化合物及其制备方法和应用
CN110156735B (zh) * 2019-04-23 2023-05-12 天津国际生物医药联合研究院 芒柄花黄素衍生物及其制备方法和应用
CN110240579B (zh) * 2019-06-10 2023-03-31 中国科学院成都有机化学有限公司 一种多取代γ-丁内酯类化合物、制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419132A2 (en) * 1989-09-19 1991-03-27 Allergan, Inc. Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3513198A (en) * 1965-10-22 1970-05-19 Hoffmann La Roche Aryloxy- and arylthio-acetylenic amines and the salts thereof
FR2378519B1 (https=) * 1976-11-24 1982-08-06 Unicler
JPH03163017A (ja) * 1989-08-24 1991-07-15 Nisshin Flour Milling Co Ltd 抗癌活性増強剤
US5399561A (en) * 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US4996230A (en) * 1990-02-16 1991-02-26 Eli Lilly And Company Leukotriene antagonists
JP2514500B2 (ja) * 1991-09-14 1996-07-10 呉羽化学工業株式会社 多剤耐性抑制剤及び発現阻害剤
JP2718830B2 (ja) * 1992-07-10 1998-02-25 ラボラトワール、グラクソ、ソシエテ、アノニム アニリド誘導体
DE4323409A1 (de) * 1993-07-13 1995-01-19 Boehringer Mannheim Gmbh Verwendung von Cumarinen und Carbostyrilen als PLA¶2¶-Inhibitoren, neue Cumarine und Carbostyrile, Verfahren zu ihrer Herstellung und Arzneimittel
US5852033A (en) * 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419132A2 (en) * 1989-09-19 1991-03-27 Allergan, Inc. Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200001861A (ko) 2018-06-28 2020-01-07 영남대학교 산학협력단 잔톤 유도체의 신규한 제조방법, 이로 제조된 신규한 잔톤 유도체 및 이들을 포함하는 조성물

Also Published As

Publication number Publication date
HUP0202578A3 (en) 2005-02-28
CZ300939B6 (cs) 2009-09-16
SK286402B6 (sk) 2008-09-05
PL211887B1 (pl) 2012-07-31
DK1212312T3 (da) 2003-07-21
AU7000000A (en) 2001-04-10
ES2195933T3 (es) 2003-12-16
NO20021050L (no) 2002-05-03
US6608089B2 (en) 2003-08-19
HUP0202578A2 (hu) 2002-11-28
JP4782337B2 (ja) 2011-09-28
ATE236147T1 (de) 2003-04-15
NO327911B1 (no) 2009-10-19
CN1371371A (zh) 2002-09-25
PT1212312E (pt) 2003-08-29
CA2382129C (en) 2010-07-06
HK1043368A1 (en) 2002-09-13
KR20020030801A (ko) 2002-04-25
EP1212312A1 (en) 2002-06-12
EP1212312B1 (en) 2003-04-02
RU2252221C2 (ru) 2005-05-20
SK3092002A3 (en) 2003-10-07
CN1229370C (zh) 2005-11-30
AU775790B2 (en) 2004-08-12
DE60001974T2 (de) 2004-02-19
DE60001974D1 (de) 2003-05-08
US20020183318A1 (en) 2002-12-05
JP2003508524A (ja) 2003-03-04
CA2382129A1 (en) 2001-03-15
PL356699A1 (en) 2004-06-28
NO20021050D0 (no) 2002-03-01
CZ2002785A3 (cs) 2002-06-12
WO2001017985A1 (en) 2001-03-15
GB9920912D0 (en) 1999-11-10

Similar Documents

Publication Publication Date Title
KR100819575B1 (ko) 플라본, 잔톤 및 쿠마린의 신규 유도체
EP1212311B1 (en) Chalcone coumarins
KR100819576B1 (ko) 신규 찰콘 화합물
HK1043368B (en) Novel derivatives of flavones, xanthones and coumarins
CN101544652B (zh) 硫脲类表鬼臼毒素化合物及其制备方法和用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20120326

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20130326

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140329

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140329

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000